Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin (pegIFN/RBV), in treatment-naive hepatitis C virus (HCV) genotype (GT) 1-infected patients. METHODS: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned (2:1)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Gastroenterol
Main Authors: Jacobson, Ira, Zeuzem, Stefan, Flisiak, Robert, Knysz, Brygida, Lueth, Stefan, Zarebska-Michaluk, Dorota, Janczewska, Ewa, Ferenci, Peter, Diago, Moises, Zignego, Anna Linda, Safadi, Rifaat, Baruch, Yaacov, Abdurakhmanov, Dzhamal, Shafran, Stephen, Thabut, Dominique, Bruck, Rafael, Gadano, Adrian, Thompson, Alexander James, Kopit, Justin, McPhee, Fiona, Michener, Tracy, Hughes, Eric A, Yin, Philip D, Noviello, Stephanie
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Inc 2016
Assuntos:
Clinical Trials Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4806200/
https://ncbi.nlm.nih.gov/pubmed/27022224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v22.i12.3418
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados